OTTAWA, ONTARIO, May 13, 2010 (MARKETWIRE via COMTEX) -- PharmaGap Inc. /quotes/comstock/11v!gap (CA:GAP 0.20, 0.00, 0.00%) /quotes/comstock/11i!phrgf (PHRGF 0.20, -0.03, -11.79%) ("PharmaGap" or "the Company") is pleased to announce the latest results from testing of its lead drug compound GAP-107B8 at the National Cancer Institute ("NCI") in Bethesda, MD. These results reflect a second test conducted by NCI to confirm results of the same test earlier this year.
